EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Cytotoxic Effects of Cytoplasmic Extracts from Traditional Yogurt-derived Lactobacillus Strains on HT-29 Human Colorectal Cancer Cells

Arezoo Haghighi, Mozhgan Ghiasian, Fereshte Ghandehari

Journal of Shahrekord University of Medical Sciences · 2026

DOI: 10.34172/jsums.1125 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Traditional yogurt is a rich source of probiotic Lactobacillus species with potential anticancer properties. This study aimed to isolate Lactobacillus strains from traditional yogurt and evaluate the cytotoxic effects of their cytoplasmic extracts on human colorectal cancer cells (HT-29). Methods: This in vitro study was conducted between 2023 and 2024. A total of 21 yogurt samples from various regions near Isfahan were processed via serial dilution and cultured on MRS agar anaerobically. Based on the results, 8 Lactobacillus isolates were identified through biochemical characterization and 16S rRNA sequencing. Three representative strains, including L. casei (MGB0470), L. casei (LcA), and L. fermentum (AGR1487), were selected for cytotoxicity evaluation. Cytoplasmic extracts were obtained following cell lysis via freeze–thaw cycles and sonication. HT-29 cells were treated with extracts (0.5-2 mg/mL) for 24 hours, and cell viability was measured using the MTT assay. Data were analyzed using one-way ANOVA and Tukey’s post hoc test. Results: All extracts exhibited a dose-dependent reduction in HT-29 cell viability (P < 0.001). At 2 mg/mL, viability decreased by over 70%. Additionally, L. fermentum (AGR1487) demonstrated the most potent inhibitory effect, with IC50 values ranging from 1.2 to 1.4 mg/mL. Phylogenetic analysis confirmed the genetic identity of the isolates. Conclusion: Cytoplasmic extracts from Lactobacillus strains isolated from traditional yogurt significantly inhibited colorectal cancer cell viability in a dose-dependent manner. These results suggest that native probiotic strains, especially L. fermentum (AGR1487), hold promise as potential adjunctive agents in anticancer therapy. Further molecular and preclinical investigations are warranted to elucidate their mechanisms and therapeutic potential.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →